In the development of central nervous system (CNS) drugs, the blood–brain barrier (BBB)
restricts many drugs from entering the brain to exert therapeutic effects. Although many …

Our body keeps separating the toxic chemicals in the blood from the brain. A significant
number of drugs do not enter the central nervous system (CNS) due to the blood-brain …

Glioblastoma (GBM) is the most common aggressive malignant tumor in brain
neuroepithelial tumors and remains incurable. A variety of treatment options are currently …

The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …

Metastases to the brain remain a significant problem in lung cancer, as treatment by most
small-molecule targeted therapies is severely limited by efflux transporters at the blood …

Purpose There is currently no curative treatment for patients diagnosed with triple-negative
breast cancer brain metastases (TNBC-BM). CAR T cells hold potential for curative treatment …

One of the greatest challenges with successful pharmaceutical treatments of central nervous
system (CNS) diseases is the delivery of drugs into their target sites with appropriate …

Significant evidence suggests that the failure of clinically tested epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (eg erlotinib, lapatinib, gefitinib) in glioblastoma …

Introduction With the increasing incidence and prevalence of neurological disorders
globally, there is a paramount need for new pharmacotherapies. BBB effectively protects the …

Multiple sclerosis (MS) is an autoimmune disease driven by lymphocyte activation against
myelin autoantigens in the central nervous system leading to demyelination and …